BiOptix continues support of Colorado-based research institutions
BOULDER, Colo., June 15, 2012 /PRNewswire/ — BiOptix, a Colorado-based firm, announces completion of a successful week of research shows in Colorado’s Biotech Corridor.
BiOptix today announced support of events this week at National Jewish Health, the University of Colorado Denver-Anschutz Medical Campus and at the University of Colorado, Boulder. These events brought Colorado-based researchers together with representatives of dozens of global life science research suppliers, and are a critical link in the research supply and innovation chain. The strength and participation at these events highlight the significant research activities that exist in Colorado, and BiOptix, as a Boulder, Colorado-based company is proud to support the continued development and expansion of these efforts.
Supporting Colorado’s Growing Biotech Corridor–and our hometown of Boulder.
Colorado’s growing biotech corridor is concentrated in the Denver-Boulder metropolitan areas allowing BiOptix strategic access to these markets. “After completing a successful show at the University of California San Francisco, last week, we are excited to turn our attention toward our home market of Colorado for this series of events,” noted Ken Wilczek, Vice President of Sales & Marketing for BiOptix. “We are grateful to have the support of our colleagues in Denver and especially in our hometown of Boulder. Colorado represents a significant opportunity to us as a supplier, not to mention what Colorado means to the global research community–it is awesome to be here.”
So far in 2012, BiOptix has participated in 8 nation-wide life science industry events and has showcased a novel and patented ultra-sensitive biosensor platform known as Enhanced Surface Plasmon Resonance, or ESPR. Unlike traditional Surface Plasmon Resonance, ESPR instrumentation from BiOptix enables the high sensitivity of SPR with the high stability and lower noise of common path interferometry. BiOptix anticipates more than 30 customer facing events in 2012, with additional planned in 2013.
BiOptix Diagnostics Corporation, a privately held firm based in Boulder, Colorado has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR – Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction–with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: www.bioptix.com
SOURCE BiOptix Diagnostics Corporation